Overview
Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic T cells to lyse the cells, such as melanocytes. Uveal melanoma is a rare ocular tumour with often poor prognosis and limited treatment options. Even after surgical ablation or removal of the ocular tumour, almost 50% of patients with uveal melanoma develop metastatic disease. On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA. Tebentafusp was subsequently approved for the same indication in the EU in April 2022.
Indication
Tebentafusp is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Associated Conditions
- Metastatic Uveal Melanoma
- Unresectable Uveal Melanoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/07/10 | Not Applicable | Not yet recruiting | Grupo Español Multidisciplinar de Melanoma | ||
2025/04/24 | Phase 2 | Not yet recruiting | |||
2024/10/04 | Phase 2 | Recruiting | |||
2024/02/07 | Phase 3 | Recruiting | |||
2023/10/06 | Phase 2 | Recruiting | Diwakar Davar | ||
2023/03/27 | Phase 1 | Recruiting | DynamiCure Biotechnology | ||
2022/09/22 | Phase 3 | Recruiting | |||
2022/04/07 | Phase 2 | Recruiting | |||
2021/07/14 | N/A | AVAILABLE | |||
2020/02/10 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Immunocore Commercial LLC | 80446-401 | INTRAVENOUS | 100 ug in 0.5 mL | 3/6/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 4/1/2022 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| KIMMTRAK tebentafusp 0.1 mg/0.5 mL concentrated solution for infusion vial | 375296 | Medicine | A | 6/3/2022 |
Help Us Improve
Your feedback helps us provide better drug information and insights.